Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page’s revision indicator was updated to v3.6.3, indicating a minor site update. This does not modify the study details or related data.SummaryDifference0.1%

- Check8 days agoChange DetectedA classic NEJM trial reference on preoperative chemotherapy plus surgery for NSCLC was added, and the site revision tag was updated from v3.6.0 to v3.6.2.SummaryDifference0.1%

- Check15 days agoChange DetectedAdds a literature citation for pembrolizumab in non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028) to provide background context for the drug's use in NSCLC.SummaryDifference0.1%

- Check22 days agoChange DetectedThe study record adds a named contact entry (Myung-Ju Ahn) and new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study), and adjusts the Intervention/Treatment label and related status wording.SummaryDifference1%

- Check29 days agoChange DetectedThe page now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a recent editorial/system update to the page rather than a modification to study content.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page's revision tag changed from v3.5.3 to v3.5.4, indicating a minor platform update. There is no evidence of changes to the study details or other content on the page.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.